A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

NCT07297875 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Achondroplasia

Interventions

DRUG: ABSK061

Sponsor

Abbisko Therapeutics Co, Ltd